According to pharmaceutical group AstraZeneca, new data from an ongoing trial after the third booster dose with the AstraZeneca COVID-19 vaccine showed an increased antibody response against beta, delta, alpha and gamma variants.

“The positive results of the preliminary analysis of the ongoing safety and immunogenicity trial (D7220C00001) showed that the AstraZeneca COVID-19 vaccine (ChAdOx1-S) [Recombinant]), when given as a third booster dose, there was an increased immune response for the beta, delta, alpha and gamma SARS-CoV-2 variants, whereas a separate analysis of the test samples showed an increased response to the Omicron variant. Antibody response shown,” the company said in a statement.

The results were seen in individuals who had previously been vaccinated with the AstraZeneca COVID-19 vaccine or mRNA vaccine, the same source adds. A separate phase IV trial, explained in a preprint with The Lancet on SSRN, showed that a third dose of the AstraZeneca Covid-19 vaccine significantly increased antibody levels after a series of primary vaccines with CoronaVac (Sinovac Biotech). increased, reports the press release. These data add to a growing body of evidence supporting the AstraZeneca COVID-19 vaccine as a third booster dose, regardless of the primary immunization schedule being tested.

→ Also read: Coronavirus: One billion doses of vaccine given through Covax program (WHO)

The company is submitting this additional data to health authorities around the world, given the urgent need for a third booster dose. The AstraZeneca Covid-19 vaccine has protected hundreds of millions of people worldwide against Covid-19 and these figures suggest it has an important role as a third booster dose, especially when used after other vaccines, executive vice president , Biopharmaceuticals Research and Development, AstraZeneca, Sir Mayne Pangalos, said in the statement.

“Given the continuing urgency of the pandemic and the enhanced immune response of the AstraZeneca Covid-19 vaccine to the Omicron version, we will continue to pursue regulatory submissions around the world for its use as a third booster dose,” said Mr. Pangalos. said. For his part, Professor Sir Andrew J Pollard, lead researcher and director of the Oxford Vaccine Group at the University of Oxford, indicated that these important studies suggest that AstraZeneca is the third booster dose after the first two doses of the Covid-19 vaccine. Having a single vaccine, or mRNA or inactivated vaccine, significantly boosts immunity against Covid-19.

The Oxford-AstraZeneca vaccine is suitable as an alternative to boosting immunity in the population for countries considering booster programs, adding to the protection already demonstrated with the first two doses, he continued. For his part, the President of the Near East and Maghreb, AstraZeneca, Rami Skander, said that “the latest data on the AstraZeneca Covid-19 Vaccine shows that when used as a third booster dose, it is a cause for concern.” Enhances the immune response against all variants, when used after other vaccines. This is of particular importance given the prevalence of the Omicron variant.” “We are delighted to share these new figures and to reiterate our commitment to the countries of the Middle East and Maghreb to maintain the health and well-being of all of us,” he said.

The D7220C00001 safety and immunogenicity trial showed the AstraZeneca COVID-19 vaccine as the third booster dose in a homogenous or heterogeneous program. In a sub-analysis of the COV001 and COV002 trials, the third dose of the AstraZeneca Covid-19 vaccine given at least six months after the second dose significantly increased antibody levels and sustained T.2 cell response. This resulted in higher neutralizing activity against alpha, beta and delta variants compared to the two-dose regimen. The Cove-Boost trial also showed that the third booster dose of the AstraZeneca Covid-19 vaccine induced a significant increase in immune responses compared to the control against the delta variant and the original strain following the primary vaccination series of the AstraZeneca vaccine. or Pfizer BioNTech (BNT162B2).

with MAP

same thing